Combined with these, AML patients with dysregulation of SAT1, G6PD or CD44 may be sensitive to 8 drugs (ARRY-162, Cobimetinib, Mitomycin, lrofulven, Tamoxifen, Oxaliplatin, Fulvestrant and lmatinib). The gene discussed is SAT1; the disease is acute myeloid leukemia.